FN
Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
---|---|---|---|---|---|---|---|
A global research priority agenda to advance public health responses to fatty liver disease | Journal of hepatology | 2023 | 41 | 5 | |||
ANGPTL4 is a potential driver of HCV-induced peripheral insulin resistance | Scientific reports | 2023 | 106 | 18 | |||
HCV disease burden and population segments in Switzerland | Liver international | 2022 | 153 | 62 | |||
Maladies infectieuses | Revue médicale suisse | 2021 | 287 | 72 | |||
The never-ending debate about conflict of interests' | Liver international | 2021 | 125 | 24 | |||
NAFLD and MAFLD as emerging causes of HCC: a populational study | JHEP Reports : Innovation in hepathology | 2021 | 211 | 107 | |||
Endpoints and New Options for Treatment of Chronic Hepatitis D | Hepatology | 2021 | 92 | 64 | |||
Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland | Swiss Medical Weekly | 2021 | 168 | 64 | |||
Recommandations pour le suivi des patients atteints d'hépatite C guérie | Swiss Medical Forum | 2021 | 184 | 109 | |||
HDV pathogenesis: unravelling ariadne's thread | Viruses | 2021 | 160 | 83 | |||
Hepatitis C prevalence in the psychiatric setting: cost-effectiveness of scaling-up screening and direct-acting antiviral therapy | JHEP Reports : Innovation in Hepatology | 2021 | 232 | 90 | |||
Real-world outcomes in historically underserved patients with chronic hepatitis C infection treated with Glecaprevir/Pibrentasvir | Infectious Diseases and Therapy | 2021 | 157 | 64 | |||
Residual risk of liver disease after hepatitis C virus eradication | Journal of Hepatology | 2021 | 150 | 0 | |||
MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective | Alimentary Pharmacology and Therapeutics | 2021 | 172 | 0 | |||
The case for simplifying and using absolute targets for viral hepatitis elimination goals | Journal of Viral Hepatitis | 2021 | 158 | 0 | |||
Hepatitis C core antigen test as an alternative for diagnosing HCV infection: mathematical model and cost-effectiveness analysis | PeerJ | 2021 | 258 | 61 | |||
The changing context of hepatitis D | Journal of Hepatology | 2021 | 155 | 0 | |||
Mir-21 Suppression Promotes Mouse Hepatocarcinogenesis | Cancers | 2021 | 186 | 324 | |||
Hepatitis C virus: current steps toward elimination in Germany and barriers to reaching the 2030 goal | Health science reports | 2021 | 188 | 56 | |||
EASL recommendations on treatment of hepatitis C: final update of the series | Journal of Hepatology | 2020 | 209 | 0 | |||
Buyers' club : une alternative pour l'accès au traitement ? | Revue médicale suisse | 2020 | 319 | 112 | |||
A letter of solidarity during the COVID-19 pandemic | Liver International | 2020 | 132 | 61 | |||
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic hcv infection: a meta-analysis | Journal of Hepatology | 2020 | 199 | 131 | |||
Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies | Journal of Hepatology | 2020 | 245 | 1 | |||
Reply to: "Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma" | Journal of Hepatology | 2020 | 180 | 58 | |||
SARS-CoV-2 and liver damage: a possible pathogenetic link | Hepatobiliary Surgery and Nutrition | 2020 | 172 | 73 | |||
Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis? | Swiss Medical Weekly | 2020 | 292 | 126 | |||
Securing sustainable funding for viral hepatitis elimination plans | Liver International | 2020 | 275 | 0 | |||
Natural history of NASH and HCC | Liver International | 2020 | 276 | 1 | |||
The MD-PhD program in Geneva: a 10-year analysis of graduate demographics and outcomes | BMC Medical Education | 2020 | 227 | 193 | |||
All-Cause mortality and causes of death in the Swiss Hepatitis C Cohort Study (SCCS) | Open Forum Infectious Diseases | 2020 | 297 | 137 | |||
Modelling the Impact and Cost-Effectiveness of Extended Screening and Treatment with Direct-Acting Antivirals in a Swiss Custodial Setting | Clinical Infectious Diseases | 2019 | 356 | 262 | |||
Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis c patients | PLOS ONE | 2019 | 367 | 128 | |||
Interleukin-1 receptor antagonist modulates liver inflammation and fibrosis in mice in a model-dependent manner | International Journal of Molecular Sciences | 2019 | 447 | 174 | |||
A review on hepatitis D: from virology to new therapies | Journal of Advanced Research | 2019 | 386 | 215 | |||
Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study | PLOS ONE | 2019 | 398 | 185 | |||
Devil hepatitis D: an orphan disease or largely underdiagnosed? | Gut | 2019 | 344 | 0 | |||
Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: a pooled analysis of clinical trials | Liver International | 2019 | 240 | 58 | |||
Very low hepatitis C viral loads in treatment-naïve persons: do they compromise hepatitis C virus antigen testing? | Clinical Infectious Diseases | 2019 | 448 | 132 | |||
Programme national de lutte contre le VIH, les IST et l'hépatite virale: unir les forces contre le VIH et les hépatites virales | Bulletin des médecins suisses | 2019 | 376 | 149 | |||
Identification of an endoglin variant associated with HCV-related liver fibrosis progression by next-generation sequencing | Frontiers in Genetics | 2019 | 265 | 95 | |||
Natural history of hepatic and extrahepatic hepatitis C virus diseases and impact of interferon-free HCV therapy | Cold Spring Harbor Perspectives in Medicine | 2019 | 270 | 2 | |||
Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates | Clinical Gastroenterology and Hepatology | 2019 | 321 | 0 | |||
Activation of the oncogenic miR-21-5p promotes HCV replication and steatosis induced by the viral core 3a protein | Liver International | 2019 | 385 | 213 | |||
Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis | Journal of Viral Hepatitis | 2019 | 265 | 106 | |||
Nonalcoholic fatty liver disease burden | Swiss Medical Weekly | 2019 | 247 | 112 | |||
Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions | Swiss Medical Weekly | 2019 | 363 | 252 | |||
Tolerogenic propreties of liver macrophages in non-alcoholic steatohepatitis | Liver International | 2019 | 368 | 378 | |||
Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland | Swiss Medical Weekly | 2019 | 1 059 | 267 | |||
Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysis | Journal of Viral Hepatitis | 2019 | 376 | 1 | |||
The heavy burden of hepatitis D in Uzbekistan | Liver International | 2019 | 282 | 0 | |||
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study | The Lancet Gastroenterology & Hepatology | 2018 | 295 | 0 | |||
Hepatitis B prevalence, risk factors, infection awareness and disease knowledge among inmates: a cross-sectional study in Switzerland's largest pre-trial prison | Journal of Global Health | 2018 | 352 | 173 | |||
Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) | Hepatology | 2018 | 410 | 445 | |||
Collagen proportionate area correlates to hepatic venous pressure gradient in non-abstinent cirrhotic patients with alcoholic liver disease | World Journal of Hepatology | 2018 | 395 | 270 | |||
Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030 | Journal of Hepatology | 2018 | 918 | 314 | |||
Deficient natural killer cell NKp30-mediated function and altered NCR3 splice variants in hepatocellular carcinoma | Hepatology | 2018 | 440 | 0 | |||
Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries | Antiviral Research | 2018 | 387 | 0 | |||
A buyers' club to improve access to hepatitis C treatment for vulnerable populations | Swiss Medical Weekly | 2018 | 1 130 | 393 | |||
EASL Clinical Practice Guidelines on hepatitis E virus infection | Journal of Hepatology | 2018 | 320 | 2 | |||
The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease | Journal of Viral Hepatitis | 2018 | 282 | 145 | |||
Coinfections between Persistent Parasitic Neglected Tropical Diseases and Viral Infections among Prisoners from Sub-Saharan Africa and Latin America | Journal of Tropical Medicine | 2018 | 659 | 244 | |||
Expert opinion on the management of renal manifestations of chronic HCV infection | Antiviral Therapy | 2018 | 320 | 0 | |||
EASL Recommendations on Treatment of Hepatitis C 2018 | Journal of Hepatology | 2018 | 292 | 0 | |||
Combler les lacunes dans les tests de dépistage de l'hépatite | Bulletin des médecins suisses | 2018 | 412 | 148 | |||
Expanded benefits of curing the extrahepatic manifestations of HCV infection | Gut | 2018 | 267 | 185 | |||
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis | Hepatology | 2018 | 245 | 0 | |||
Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies | Journal of Hepatology | 2018 | 433 | 1 | |||
Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030? | PLOS ONE | 2018 | 354 | 166 | |||
Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review | Journal of Viral Hepatitis | 2018 | 471 | 0 | |||
Cardiovascular Manifestations of Hepatitis C Virus | Clinics in Liver Disease | 2017 | 446 | 2 | |||
Hépatite B : nouvelles recommandations de prise en charge | Revue médicale suisse | 2017 | 492 | 2 | |||
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study | The Lancet Gastroenterology & Hepatology | 2017 | 268 | 0 | |||
Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review | Journal of Advanced Research | 2017 | 462 | 299 | |||
Access to hepatitis C treatment for patients in drug substitution programmes: the fight is far from over | Swiss Medical Weekly | 2017 | 391 | 150 | |||
Estimating HCV disease burden-volume 4 (editorial) | Journal of Viral Hepatitis | 2017 | 346 | 0 | |||
Extrahepatic manifestations in hepatitis C virus infection | Journal of Advanced Research | 2017 | 398 | 105 | |||
Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030 | Swiss Medical Weekly | 2017 | 887 | 221 | |||
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study | The Lancet Gastroenterology & Hepatology | 2017 | 284 | 0 | |||
Hepatic protein tyrosine phosphatase receptor gamma links obesity-induced inflammation to insulin resistance | Nature Communications | 2017 | 1 475 | 383 | |||
The impact of hepatitis C virus outside the liver: Evidence from Asia | Liver international | 2017 | 394 | 1 | |||
Editor's note | Liver International | 2017 | 172 | 0 | |||
Hépatites B et C : nouveaux traitements | Revue médicale suisse | 2017 | 370 | 0 | |||
Health-related quality of life in chronic HCV-infected patients switching to pegylated-interferon-free regimens (ARNS CO20 CUPIC cohort study and SIRIUS trial) | The Patient - Patient-Centered Outcomes Research | 2017 | 233 | 1 | |||
A Systematic Review and Meta-Analysis of HCV Clearance | Liver international | 2017 | 500 | 1 | |||
Nucleic acid polymers: much-needed hope for hepatitis D? | The Lancet Gastroenterology & Hepatology | 2017 | 334 | 1 | |||
BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease | Oncotarget | 2017 | 513 | 2 | |||
Trends in hepatitis C-related mortality in Switzerland | Journal of Hepatology | 2017 | 1 140 | 575 | |||
The negative impact of HBV/HCV coinfection on cirrhosis and its consequences | Alimentary Pharmacology and Therapeutics | 2017 | 407 | 0 | |||
Hepatitis C Virus Increases Occludin Expression via the Upregulation of Adipose Differentiation-Related Protein | PloS one | 2016 | 1 120 | 208 | |||
Effect of quercetin on hepatitis C virus life cycle: from viral to host targets | Scientific Reports | 2016 | 345 | 108 | |||
Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes | Gut | 2016 | 319 | 1 | |||
Quels espoirs pour l'hépatite delta ? | Revue médicale suisse | 2016 | 389 | 1 | |||
Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations | PloS one | 2016 | 552 | 507 | |||
Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin | Journal of hepatology | 2016 | 475 | 3 | |||
The hepatitis delta virus: Replication and pathogenesis | Journal of hepatology | 2016 | 503 | 2 | |||
Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver disease | World journal of gastroenterology | 2016 | 552 | 6 | |||
Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery | Clinical gastroenterology and hepatology | 2016 | 476 | 0 | |||
A significant effect of the killer cell immunoglobulin-like receptor ligand human leucocyte antigen-C on fibrosis progression in chronic C hepatitis with or without liver transplantation | Liver international | 2016 | 492 | 1 | |||
Drug Pricing Evolution in Hepatitis C | PloS one | 2016 | 1 303 | 580 | |||
Corrigendum: reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes | Nature communications | 2015 | 520 | 137 | |||
ABO incompatible kidney transplantation from an anti-hepatitis C virus antibody-positive RNA-negative donor into an anti-hepatitis C virus antibody-negative recipient | Transplant international | 2015 | 613 | 1 | |||
Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland | PloS one | 2015 | 559 | 1 293 | |||
Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland | Schweizerische medizinische Wochenschrift | 2015 | 554 | 202 | |||
The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients | Journal of Viral Hepatitis | 2015 | 257 | 0 | |||
Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C | PloS one | 2015 | 637 | 296 | |||
A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance | Hepatology | 2015 | 294 | 0 | |||
Are statins a remedy for all seasons? | Journal of hepatology | 2015 | 588 | 214 | |||
Extrahepatic morbidity and mortality of chronic hepatitis C | Gastroenterology | 2015 | 430 | 0 | |||
The evolutionary patterns of hepatitis C virus subtype 2a and 6a isolates linked to an outbreak in China in 2012 | Virology | 2015 | 480 | 0 | |||
Impact of IL28B, APOH and ITPA polymorphisms on efficacy and safety of TVR- or BOC-based triple therapy in treatment-experienced HCV-1 patients with compensated cirrhosis from the ANRS CO20_CUPIC study | PLOS ONE | 2015 | 230 | 131 | |||
Repenser la politique de remboursement des agents antiviraux directs contre l'hépatite C chronique | Revue médicale suisse | 2015 | 475 | 1 | |||
Extrahepatic manifestations of HCV | Minerva gastroenterologica e dietologica | 2015 | 499 | 0 | |||
The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection | Alimentary pharmacology & therapeutics | 2014 | 561 | 0 | |||
Is genotype 3 of the hepatitis C virus the new villain ? | Hepatology | 2014 | 282 | 0 | |||
Clinical significance of the CCR5delta32 allele in hepatitis C | PloS one | 2014 | 496 | 196 | |||
HCV 3a core protein increases lipid droplet cholesteryl ester content via a mechanism dependent on sphingolipid biosynthesis | PloS one | 2014 | 537 | 206 | |||
Curbing hepatitis C virus spread in Egypt | The Lancet. Global health | 2014 | 527 | 0 | |||
Historical epidemiology of hepatitis C virus (HCV) in selected countries | Journal of viral hepatitis | 2014 | 561 | 1 | |||
Hepatitis D virus coinfection and superinfection | Cold Spring Harbor perspectives in medicine | 2014 | 440 | 0 | |||
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm | Journal of viral hepatitis | 2014 | 546 | 1 | |||
The impact of obesity and metabolic syndrome on chronic hepatitis C | Clinics in liver disease | 2014 | 500 | 0 | |||
Origin of hepatitis C virus genotype 3 in Africa as estimated through an evolutionary analysis of the full-length genomes of nine subtypes, including the newly sequenced 3d and 3e | Journal of general virology | 2014 | 503 | 0 | |||
EASL Clinical Practice Guidelines: management of hepatitis C virus infection | Journal of hepatology | 2014 | 559 | 0 | |||
Transplantation cellulaire : traitements actuels et perspectives d'avenir | Revue médicale suisse | 2014 | 809 | 14 | |||
Does telaprevir possess a direct antidiabetic effect? | Liver international | 2014 | 554 | 0 | |||
Novel Approach Identifies SNPs in SLC2A10 and KCNK9 with Evidence for Parent-of-Origin Effect on Body Mass Index | PLOS genetics | 2014 | 674 | 1 210 | |||
Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases | Journal of hepatology | 2014 | 530 | 239 | |||
Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon-α and ribavirin in chronic hepatitis C virus patients | Liver international | 2014 | 514 | 0 | |||
Epidemiology of hepatitis C in Europe | Digestive and Liver Disease | 2014 | 528 | 228 | |||
Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes | Nature communications | 2014 | 566 | 1 172 | |||
Insulin resistance, non-alcoholic fatty liver disease and hepatitis C virus infection | Reviews on recent clinical trials | 2014 | 519 | 0 | |||
Strategies to manage hepatitis C virus (HCV) disease burden | Journal of viral hepatitis | 2014 | 539 | 1 | |||
Hepatitis C in 2013: HCV causes systemic disorders that can be cured | Nature reviews. Gastroenterology & hepatology | 2014 | 567 | 2 | |||
Morbidité et mortalité extrahépatiques associées à l'infection par le virus de l'hépatite C | Revue médicale suisse | 2014 | 518 | 1 | |||
Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development | PloS one | 2013 | 622 | 589 | |||
PTEN protein phosphatase activity regulates hepatitis C virus secretion through modulation of cholesterol metabolism | Journal of hepatology | 2013 | 639 | 2 | |||
Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma | Journal of hepatology | 2013 | 594 | 0 |